BE898389R - Antiemetic compsns. contg. metoclopramide - also contain resin and water - Google Patents

Antiemetic compsns. contg. metoclopramide - also contain resin and water

Info

Publication number
BE898389R
BE898389R BE0/211995A BE211995A BE898389R BE 898389 R BE898389 R BE 898389R BE 0/211995 A BE0/211995 A BE 0/211995A BE 211995 A BE211995 A BE 211995A BE 898389 R BE898389 R BE 898389R
Authority
BE
Belgium
Prior art keywords
metoclopramide
water
compsns
resinate
antiemetic
Prior art date
Application number
BE0/211995A
Other languages
French (fr)
Original Assignee
Trenker Ady
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trenker Ady filed Critical Trenker Ady
Priority to BE0/211995A priority Critical patent/BE898389R/en
Application granted granted Critical
Publication of BE898389R publication Critical patent/BE898389R/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compsns. comprising metoclopramide resinate (I), as described in the parent patent, are now used in daily doses of 16 mg.. (I) comprises (%): metoclopramide HCl, H2O 40; resin 80; water 10. Tests have now shown that 40 mg resinate (equivalent to 16 mg hydrochloride) have the same effect as 30 mg of pure hydrochloride.(0/0)

Description

       

   <Desc/Clms Page number 1> 
 



   BREVET DE PERFECTIONNEMENT rattaché au brevet belge No 876.857 déposé le 8 juin 1979. 



  Monsieur Ady TRENKER à B-1180 Bruxelles (Belgique) Résinate de Metoclopramide 

 <Desc/Clms Page number 2> 

 
Le brevet principal décrit et met sous protection le résinate de métoclopramide et les médicaments antiémétiques à effet retard qui le contiennent. 



   Le produit ainsi défini comprend : 
 EMI2.1 
 40 % de métoclopramide HCl. H20 
50 % de résine
10 % d'eau. 



   Dans le brevet principal on a considéré en se basant sur des essais in vitro que 100 mg de résinate de métoclopramide contenant 40 mg de chlorhydrate monohydraté de métoclopramide équivalent à 3 x 10 mg de chlorhydrate de métoclopramide monohydraté ordinaire. 



   Des essais pharmaceutiques ont montré que le résinate a un comportement encore plus différent de celui du chlorhydrate ordinaire en ce sens que 40 mg de la forme résinate (= 16 mg de chlorhydrate de métoclopramide) équivalent à 30 mg ou 3 x 10 mg de chlorhydrate ordinaire. 



   Cette constatation a été confirmée par des essais cliniques. 



   Le présent perfectionnement est basé sur cette découverte et propose donc un médicament à base de résinate de métoclopramide contenant pour une dose journalière 16 mg de résinate de métoclopramide sous forme de monochlorhydrate monohydraté. 



   Ce médicament diminue sensiblement les effets secondaires du chlorhydrate de métoclopramide non seulement parce que la libération du produit actif est étalée dans le temps mais également parce que la dose journalière mise en oeuvre est moindre.



   <Desc / Clms Page number 1>
 



   IMPROVED PATENT attached to Belgian patent No 876.857 filed on June 8, 1979.



  Mr. Ady TRENKER at B-1180 Brussels (Belgium) Metoclopramide resinate

 <Desc / Clms Page number 2>

 
The main patent describes and puts under protection the metoclopramide resinate and the antiemetic drugs with delay effect which contain it.



   The product thus defined includes:
 EMI2.1
 40% metoclopramide HCl. H20
50% resin
10% water.



   In the main patent, it was considered based on in vitro tests that 100 mg of metoclopramide resinate containing 40 mg of metoclopramide hydrochloride monohydrate equivalent to 3 x 10 mg of ordinary metoclopramide hydrochloride monohydrate.



   Pharmaceutical tests have shown that the resinate behaves even more differently from ordinary hydrochloride in that 40 mg of the resinate form (= 16 mg of metoclopramide hydrochloride) is equivalent to 30 mg or 3 x 10 mg of ordinary hydrochloride .



   This finding has been confirmed by clinical trials.



   The present improvement is based on this discovery and therefore proposes a medicament based on metoclopramide resinate containing for a daily dose 16 mg of metoclopramide resinate in the form of monohydrochloride monohydrate.



   This drug significantly reduces the side effects of metoclopramide hydrochloride not only because the release of the active product is spread over time but also because the daily dose used is less.

Claims (1)

REVENDICATION Médicament à base de résinate de métoclopramide suivant le brevet principal, caractérisé en ce qu'il contient 16 mg de résinate de métoclopramide sous forme de monochlorhydrate monohydraté pour une dose journalière.  CLAIM Medication based on metoclopramide resinate according to the main patent, characterized in that it contains 16 mg of metoclopramide resinate in the form of monohydrochloride monohydrate for a daily dose.
BE0/211995A 1983-12-06 1983-12-06 Antiemetic compsns. contg. metoclopramide - also contain resin and water BE898389R (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BE0/211995A BE898389R (en) 1983-12-06 1983-12-06 Antiemetic compsns. contg. metoclopramide - also contain resin and water

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE898389 1983-12-06
BE0/211995A BE898389R (en) 1983-12-06 1983-12-06 Antiemetic compsns. contg. metoclopramide - also contain resin and water

Publications (1)

Publication Number Publication Date
BE898389R true BE898389R (en) 1984-03-30

Family

ID=25653837

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/211995A BE898389R (en) 1983-12-06 1983-12-06 Antiemetic compsns. contg. metoclopramide - also contain resin and water

Country Status (1)

Country Link
BE (1) BE898389R (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113354553A (en) * 2021-06-03 2021-09-07 北京宝诺康医药科技有限公司 Preparation method of metoclopramide monohydrochloride monohydrate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113354553A (en) * 2021-06-03 2021-09-07 北京宝诺康医药科技有限公司 Preparation method of metoclopramide monohydrochloride monohydrate

Similar Documents

Publication Publication Date Title
US5698225A (en) Pharmaceutical composition
AP1526A (en) Sertraline salts and sustained-release dosage forms of sertraline.
US4474813A (en) Pharmaceutical preparations comprising flutamide
RU2000100756A (en) METHODS AND COMPOSITIONS FOR MODULATION OF SEXUAL HUMAN REACTION
KR890701559A (en) 3-indolepyruvic acid derivatives and pharmaceutical uses thereof
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
AR028299A1 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
JP2002537258A5 (en)
US4425363A (en) Treatment of tardive dyskinesia in mammals
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
BE898389R (en) Antiemetic compsns. contg. metoclopramide - also contain resin and water
HU199293B (en) Process for production of tepically applicable medical compositions suitable for treatment of peptical ulcus by mammates
US3125488A (en) Method of inducing analgesia by
JPH0684298B2 (en) Parkinson&#39;s disease drug
WO1995005831A1 (en) Pharmaceutical compositions containing morphine-6-glucuronide for the treatment of pain
FR2792199A1 (en) USE OF OSANETANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF MOOD DISORDERS
RU92004569A (en) PHARMACEUTICAL PRODUCT OF ANTI-STRESS, STRESS-PROTECTIVE AND NOOTROPIC ACTION
BE902605A (en) Medicaments for treating urinary tract disorders - contg. oxybutynin chloride
US3129137A (en) Method of inhibiting gastro-intestinal irritation
JP2627914B2 (en) Selective enhancer of prostaglandins
AU2003246774B2 (en) Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
US3444302A (en) Method of preventing influenza viral infections
US4310549A (en) Treatment of hypertension with 1-tert.-butylamino-3-(2,5-dichlorophenoxy)-2-propanol
CA2514022A1 (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
US3777026A (en) N-substituted amino-n-nitroso-amino-acetonitriles as anti-anginal agents

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: TRENKER ADY

Effective date: 19841206